| pubmed-article:15911237 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0202001 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0937950 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C1547530 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0205227 | lld:lifeskim |
| pubmed-article:15911237 | lifeskim:mentions | umls-concept:C0439581 | lld:lifeskim |
| pubmed-article:15911237 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15911237 | pubmed:dateCreated | 2005-5-24 | lld:pubmed |
| pubmed-article:15911237 | pubmed:abstractText | The introduction of longer-acting erythropoietic agents into the practice of oncology has demanded an understanding of the interaction of chemotherapy with the pharmacokinetics and haematological effects of these erythropoietins. We report results of a randomised trial comparing the haematological effects of darbepoetin alfa, 6.75 mug/kg, administered once every 3 weeks to anaemic cancer chemotherapy patients on either an asynchronous (day 15) or synchronous (day 1) schedule relative to their every-3-week chemotherapy. A total of 81 patients were randomised and received the study drug (43 asynchronous; 38 synchronous). No difference was observed between groups in the primary endpoint of mean haemoglobin change after 6 weeks of therapy (P=0.45) and change scores were similar to those observed with standard weekly darbepoetin alfa therapy. In a subset of patients evaluated with intensive pharmacokinetic sampling, an increase in endogenous erythropoietin concentration (up to 4-fold) lasting approximately 1 week following chemotherapy administration was observed in both groups. Synchronous administration of darbepoetin alfa was associated with a 1.3-fold increase in the area under the darbepoetin alfa concentration-time curve compared with asynchronous administration. Our data suggest that darbepoetin alfa is effective administered every 3 weeks regardless of timing of administration with respect to chemotherapy and that receptor-mediated uptake by the erythron may be an important clearance mechanism for erythropoietic proteins. | lld:pubmed |
| pubmed-article:15911237 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15911237 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15911237 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15911237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15911237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15911237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15911237 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15911237 | pubmed:month | May | lld:pubmed |
| pubmed-article:15911237 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:GlaspyJohnJ | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:HenryDavidD | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:PatelRaviR | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:TchekmedyianS... | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:RossiGregG | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:AustinMattM | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:ApplebaumStev... | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:BerdeauxDonal... | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:LloydRichardR | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:BergRussellR | lld:pubmed |
| pubmed-article:15911237 | pubmed:author | pubmed-author:Darbepoetin... | lld:pubmed |
| pubmed-article:15911237 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15911237 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:15911237 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15911237 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15911237 | pubmed:pagination | 1140-9 | lld:pubmed |
| pubmed-article:15911237 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:meshHeading | pubmed-meshheading:15911237... | lld:pubmed |
| pubmed-article:15911237 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15911237 | pubmed:articleTitle | Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. | lld:pubmed |
| pubmed-article:15911237 | pubmed:affiliation | UCLA, School of Medicine, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095-6956, USA. jglaspy@mednet.ucla.edu | lld:pubmed |
| pubmed-article:15911237 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15911237 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15911237 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15911237 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15911237 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15911237 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15911237 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15911237 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15911237 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15911237 | lld:pubmed |
